Current/ Expected Orderbook/ Pending Orders?

Rajesh Aggarwal mentioned positive signs in exports and expects good orders in the current quarter. Export turnover target for FY '24 is toned down to INR150 crores from INR200 crores earlier. Orders expected in Q3 (September onwards), though these may not convert into sales in July or August. The company is hopeful to cross the INR150 crores export turnover this year. Focus on launching 4 new products in Q2, which will add to order pipeline. Strong demand and all-time high sales in July indicate a robust order inflow in domestic markets as well.

Any current/future new fundraising through debt or equity?

No explicit mention of fundraising through debt or equity in the provided transcript. The company has spent around INR25 crores on land acquisition and plans a total capex of about INR150 crores over the next 2 years for expansion (Dahej, Sotanala, SEZ plant). The majority of the capital expenditures appear to be funded internally or from ongoing operations, as there is no specific reference to raising funds externally. Emphasis is on organic growth powered by R&D, registrations, capacity expansions, and product launches, targeting 20% CAGR in revenue over next 5 years. No indications of plans

Any current/future capex/capital investment/strategic investment?

Chopanki technical plant capacity increased by ~50%; already in production. Dahej plant to commence production post-Diwali 2023; 95% of expenses done. Acquired ~15 acres land at Sotanala, Rajasthan (Sotanala District, Behror); INR 25 crores spent on acquisition. Planned capex of approx. INR 100 crores over 2 years at Sotanala for formulation, technical synthesis, and possibly biological plant. INR 25 crores planned for SEZ facility expansion (focused on export demand). Another INR 25 crores allocated for routine expansions at Dahej and smaller projects including biologicals. Total

Future growth expectations in sales/revenue/volumes?

Targeting ~20% CAGR revenue growth over the next 5 years (Rajesh Aggarwal, Page 12 and 13). FY 2024 revenue growth expected around 10% to 12%, with Q2 anticipated to be strong (Page 13). Export turnover target initially INR 200 crores, revised to INR 150 crores for FY 2024, with better export numbers expected from September onward (Page 16 and 17). Doubling of company turnover approximately every 5 years, from INR 500 crores in 2012 to near INR 2,000 crores currently (Page 17). Focus on new product launches (4 lined up in Q2), value-added and patented products driving growth (Page 6, 14). Biol

Future growth expectations in earnings/operating earnings/profits/EPS?

The company targets a revenue CAGR of around 20% over the next 5 years. EBITDA margin improvement is anticipated from current ~6% to 9-10% in FY24, with a longer-term goal of sustainable 12-13% margins. Margin expansion is expected through R&D investments focused on new-generation and value-added patented molecules, and biological products. Export turnover target for FY24 is revised to INR150 crores, with expectations to cross this from September onwards. A capex of INR150 crores planned over the next 2 years to expand formulation and technical synthesis capacities, supporting growth.

IN US

Sale is live|00:00:00left today

Insecticides India LtdQ2 FY23Fertilizers & Agrochemicals

Insecticides India Ltd Q2 FY23 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹669P/E: 14.8Market Cap: ₹2.1K CrSector: Fertilizers & Agrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 2

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

→Targeting ~20% CAGR revenue growth over the next 5 years (Rajesh Aggarwal, Page 12 and 13).
→FY 2024 revenue growth expected around 10% to 12%, with Q2 anticipated to be strong (Page 13).
→Export turnover target initially INR 200 crores, revised to INR 150 crores for FY 2024, with better export numbers expected from September onward (Page 16 and 17).
→Doubling of company turnover approximately every 5 years, from INR 500 crores in 2012 to near INR 2,000 crores currently (Page 17).
→Focus on new product launches (4 lined up in Q2), value-added and patented products driving growth (Page 6, 14).
→Biological products segment poised for meaningful launches starting FY 23-24, expected to contribute incremental revenue (Page 15).
→Expansion capex of INR 150 crores planned to support capacity for anticipated growth (Page 12).

Margin guidance

Category 2

→The company targets a revenue CAGR of around 20% over the next 5 years.
→EBITDA margin improvement is anticipated from current ~6% to 9-10% in FY24, with a longer-term goal of sustainable 12-13% margins.
→Margin expansion is expected through R&D investments focused on new-generation and value-added patented molecules, and biological products.
→Export turnover target for FY24 is revised to INR150 crores, with expectations to cross this from September onwards.
→A capex of INR150 crores planned over the next 2 years to expand formulation and technical synthesis capacities, supporting growth.
→Q2 is expected to be the strongest quarter with significant contributions from new product launches.
→The company aims to improve operating profitability as high-cost inventory is liquidated and product mix shifts towards value-added products.
→Conservative guidance for FY24 EBITDA margins is 9-10%, with optimism for double-digit margins in quarters going forward.

3 more insights locked — sign up free to unlock

Fundraise plans

→No explicit mention of fundraising through debt or equity in the provided transcript.
→The company has spent around INR25 crores on land acquisition and plans a total capex of about INR150 crores over the next 2 years for expansion (Dahej, Sotanala, SEZ plant).
→The majority of the capital expenditures appear to be funded internally or from ongoing operations, as there is no specific reference to raising funds externally.
→Emphasis is on organic growth powered by R&D, registrations, capacity expansions, and product launches, targeting 20% CAGR in revenue over next 5 years.
→No indications of plans for raising fresh equity or taking on new debt were discussed in the call excerpts.

Order book

Yes

→Rajesh Aggarwal mentioned positive signs in exports and expects good orders in the current quarter.
→Export turnover target for FY '24 is toned down to INR150 crores from INR200 crores earlier.
→Orders expected in Q3 (September onwards), though these may not convert into sales in July or August.
→The company is hopeful to cross the INR150 crores export turnover this year.
→Focus on launching 4 new products in Q2, which will add to order pipeline.
→Strong demand and all-time high sales in July indicate a robust order inflow in domestic markets as well.

Capex plans

Yes

→Chopanki technical plant capacity increased by ~50%; already in production.
→Dahej plant to commence production post-Diwali 2023; 95% of expenses done.
→Acquired ~15 acres land at Sotanala, Rajasthan (Sotanala District, Behror); INR 25 crores spent on acquisition.
→Planned capex of approx. INR 100 crores over 2 years at Sotanala for formulation, technical synthesis, and possibly biological plant.
→INR 25 crores planned for SEZ facility expansion (focused on export demand).
→Another INR 25 crores allocated for routine expansions at Dahej and smaller projects including biologicals.
→Total planned spend over next 2 years approximately INR 150 crores.
→Biological plant location decision pending (Chopanki or Sotanala).
→Focus on new product launches (7–8 products planned for FY '24–'25).
→Upgraded technology systems: SAP HANA, BI dashboards, CRM with Salesforce for improved customer connectivity and risk mitigation.

How does Insecticides India Ltd rank vs peers in Fertilizers & Agrochemicals?

Pro feature

1Insecticides India Ltd

Rev 3Mar 2

See full Fertilizers & Agrochemicals sector rankings

Want more stocks like Insecticides India Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio